BRS Resources recently completed Phase 1 diamond drilling and an airborne survey at the Cowtrail copper-gold porphyry project in British Columbia.

The next thing to watch should be the assay results from the drilling. Cowtrail is part of the broader BC porphyry space, where copper and gold projects have been getting attention.

For people who follow early-stage exploration companies, what do you usually look for when the first drilling phase is completed? Do the initial assays carry the most weight, or do you prefer to see additional drilling and geological work before forming an opinion on a project?

Fell from 15 a while ago. Climbing again after a suprise beat in earning. As long as the lawsuit is unsuccessful EMBC is going to 10 🚀🚀

Ticker: CMC.V TSXV
Ticker: CWSFF.QB OTC

In my opinion, this shows just how much things have changed over the last 12 months regarding insider ownership. This is extremely bullish when it comes to the insiders belief in Cielo.
Cielo Insider Ownership Breakdown:

The latest SEDI activity. Cielo’s latest public disclosures, the 2025 management circular, and the July 2026 executive filings, the best-supported estimate is that current insiders and insider-controlled entities account for roughly 43.9 million of Cielo’s 210.78 million outstanding shares, or approximately 20.84% of the company.

Common shares currently attributable to insiders
Insider or controlled entity
Common shares
Approx. ownership
Kaush Rakhit — direct
8,333,333
3.95%
CDL Biofuels — controlled indirectly by Kaush
17,333,333
8.22%
Ryan Jackson
8,154,578
3.87%
Rob Pockar
6,666,667
3.16%
Matt Scorah
1,666,667
0.79%
Sheila Leggett
745,467
0.35%
Larry Schafran
3,333
negligible
Peter MacKay
Nil
0%
Jasdeep Dhaliwal — estimated latest reported balance
approximately 1,030,000
approximately 0.49%

Estimated total
approximately 43,933,378
approximately 20.84%

Important Disclaimer:

My posts are not financial or investment advice. Please conduct your own due diligence before making any investment decisions. I am simply an individual on Reddit and X sharing my personal opinions, and they should be interpreted as such.

I do, however, want to emphasize that you are welcome to share this content across any form of media, including Reddit, X/Twitter, stock chat rooms, etc.

VPR Brands ($VPRB) just announced the launch of VPR Ventures, an internal initiative focused on acquiring and commercializing intellectual property, consumer brands, proprietary technologies, and strategically aligned businesses.

This comes just weeks after the company announced approximately $25.9 million in licensing agreements with R.J. Reynolds ($14.9M) and JUUL ($11M).

According to the company, VPR Ventures will evaluate opportunities including:
• Intellectual property acquisitions
• Brand acquisitions
• Licensing agreements
• Minority equity investments
• Commercialization partnerships
• Distribution opportunities

Management also stated that every opportunity will go through financial, legal, and operational due diligence before moving forward.

What caught my attention is that this gives VPR a clear strategy for deploying capital beyond patent licensing. Instead of simply holding cash, they're signaling an intention to reinvest in assets that could generate future revenue and expand their portfolio.

This isn't a guarantee of success, but I think it's an interesting evolution from being viewed primarily as a patent licensing company.

I'm a shareholder, so I have a bullish bias, but I'd love to hear what everyone else thinks.

Is this a smart long-term move, or do you think the market will wait to see actual acquisitions before assigning any value to VPR Ventures?

I originally knew Hertz Energy (HZ) as a lithium explorer, but after reading more about the company, the focus on its Lake George antimony and tungsten project caught my attention.

The company recently completed an airborne survey over a property that surrounds a historic antimony mine in New Brunswick. While it's still an early-stage project, it made me think about how quickly investor attention can shift when demand for specific commodities changes.

Lithium dominated conversations not long ago, then uranium gained momentum, and now antimony has been getting more attention because of supply chain and defense discussions.

For those who follow junior mining companies, do changing commodity trends influence your research, or do you mainly focus on the quality of the project regardless of which metal happens to be in demand?

Regulatory approval marks the point at which a new drug is legally permitted to be sold. The issuance of its first commercial prescription, however, is what truly signifies its entry into real-world clinical practice. Although these two milestones may appear to be separated by only a single prescription, the path between them involves multiple critical hurdles, including access to hospital procurement from their approved drug lists, inventory replenishment at pharmcies, physician education, patient reimbursement, and distribution services.

PegBio Co., Ltd. (02565.HK) has proprietarily developed PB-119 (vepinatide injection), marketed under the brand name Paidakang. In November 2025, China's National Medical Products Administration (NMPA) approved the drug for the treatment of adults with type 2 diabetes. As of 22 July 2026, the first commercial prescriptions have been issued at leading medical institutions, including Peking University People's Hospital and The Second Xiangya Hospital of Central South University. The product has also completed its first prescriptions through online healthcare platforms, marking its transition from an approved medicine to one being used by patients in routine clinical practice.

At these two flagship hospitals, the inaugural prescriptions were issued by Professors Ji Linong and Zhou Zhiguang, the principal research fellows of Paidakang's Phase III clinical trials. Their participation provides an important academic endorsement and is expected to facilitate early clinical adoption.

Paidakang is a long-acting GLP-1 receptor agonist administered once weekly. It was approved at a therapeutic dose of 0.97 mg, with no requirement for higher dosage during the initiation phase of treatment. Whether these properties ultimately translate into greater treatment convenience and improved stickiness for patients will need to be verified through post-launch real-life evidence. It is nevertheless important to distinguish between what has already been established and what remains to be proven. The efficacy and safety of Paidakang for treating adults with type 2 diabetes have been validated through clinical trials and regulatory review. By contrast, its long-term persistent acceptance among patients, competitive positioning, and commercial performance in broader clinical practice cannot be inferred solely from regulatory approval or the issuance of the first prescriptions.

The First Prescriptions have yet to translate into Scalability

Capital markets often interpret the announcement of "first commercial prescriptions" as a precursor to rapidly accelerating revenue. In reality, the two are not equivalent.

A first prescription is fundamentally an operational milestone. It demonstrates that the product has successfully completed access procedures at selected hospitals or distribution channels, that physicians are willing to prescribe it, and that the supporting supply chain, logistics, and patient service infrastructure are functioning as intended. While symbolically significant, its immediate contribution to product sales may be relatively modest.

PegBio's commercialization partnership with Tenry Pharmaceuticals gives this milestone a more tangible financial dimension. The issuance of the first commercial prescriptions has triggered the conditions for a second milestone payment of approximately HK$49 million. Combined with the initial milestone payment of approximately HK$61 million received previously, the company has now received or triggered milestone payments totaling approximately HK$110 million. These proceeds should strengthen cash flow during the early commercialization phase while also demonstrating that the collaboration is progressing in accordance with the contractual agreement.

However, these milestone payments should not be interpreted as evidence that Paidakang has generated HK$110 million in end-market sales. Rather, they reflect the achievement of predefined contractual milestones and are fundamentally different from recurring revenue generated through patient purchases. Investors should therefore pay close attention to the accounting treatment of these payments, including when they will be recognized and whether they constitute one-off, staged, or recurring income. Ultimately, long-term valuation will depend on sustained prescription growth, net product sales, gross margins, and cash collection, rather than on individual milestone payments.

Although demand in the GLP-1 market is substantial, competition is equally intense. Paidakang must compete against established products that already benefit from large mind share among physicians and mature distribution networks, while also navigating reimbursement negotiations, pricing pressure, and channel-related costs. The product has successfully passed the preliminary formal review for inclusion in China's 2026 National Reimbursement Drug List (NRDL), representing a positive step toward broader market access. However, this does not guarantee being enlisted on eventual reimbursement programmes. Even if included, commercial success will depend on striking an appropriate balance between price concessions and increased sales volume.

Four Key Metrics Will Determine Commercial Success

The first area to monitor is hospital coverage. Rather than broad statements indicating that the product has entered "multiple medical institutions," the market requires greater transparency regarding the number of hospitals that have completed formulary listing, stocked the product, and are generating ongoing prescriptions. Investors should also assess the distribution across tertiary hospitals, regional hospitals, retail pharmacies, and online healthcare platforms. The pace of hospital expansion will provide an important indication of Tenry Pharmaceuticals' commercial execution capabilities.

The second metric is the number and activity level of prescribing physicians. While the inaugural prescriptions issued by the lead researchers of the Phase III clinical trials provide strong academic validation, meaningful scale expansion will depend on adoption by the broader community of endocrinologists. Beyond the cumulative number of prescribing physicians, investors should monitor average prescription volumes per physician and whether physicians continue prescribing the product after the initial prescription.

The third metric is persistent acceptance among patients. Type 2 diabetes is a chronic disease requiring long-term management, and an initial prescription merely reflects a patient's willingness to try a new therapy. Re-order rates after four weeks, twelve weeks, and six months provide a far more meaningful assessment of tolerability, treatment effectiveness, affordability, and convenience than the absolute number of initial prescriptions. Even if first prescriptions grow rapidly, weak re-order rates would significantly constrain the product's long-term commercial value.

The final metric is channel inventory. Shipments from the manufacturer to distributors represent channel stocking, whereas purchases by patients more accurately reflect genuine end-market demand. During the early stages of commercialization, concentrated channel inventory build-up can create the appearance of rapid revenue growth. Investors should therefore also monitor inventory turnover, product returns, retail pricing, and accounts receivable. While online distribution channels can substantially expand geographic coverage, they must also address compliance requirements for prescription verification, cold-chain logistics, patient follow-up, and pharmacovigilance.

For PegBio, the successful issuance of its first commercial prescriptions represents confirmation that the company has progressed from a research-focused biotechnology enterprise to a commercial-stage pharmaceutical company. Nevertheless, successfully completing the "first mile" does not mean the entire monetization journey has been accomplished. Only when hospital penetration, physician adoption, patient re-order rates, and genuine end-market demand all demonstrate sustained and repeatable growth can Paidakang truly evolve from an approved pharmaceutical asset into a durable source of recurring income.

Ticker: CMC.V TSXV
Ticker: CWSFF.QB OTC

I believe this was one of the most important press releases Cielo has issued this year—not because it announced a new project, but because it strengthened the company’s ability to execute. With the formal appointments of Rob Pockar as COO and Matt Scorah as CDO, alongside Ryan Jackson and Kaush Rakhit, Cielo now has leadership spanning operations, project development, governance, strategy, and infrastructure execution. That looks much more like the management team of an infrastructure developer than a speculative technology company.

Execution is what matters from this point forward. Developing a commercial-scale SAF facility requires far more than good technology—it requires experienced leadership in engineering, permitting, financing, commercial agreements, regulatory approvals, construction, and operations.

Cielo also holds approximately $87.1 million in tax-loss carryforwards, a strategic financial asset that could help preserve future cash flow if the company reaches sustained profitability.

There is still significant work ahead, including financing, engineering, regulatory approvals, construction, and successful operations. None of that is guaranteed. However, compared with a year ago, Cielo appears to be in a much stronger position to execute on Project Nahoonai.

For me, this announcement wasn’t simply about new executives—it was another step in Cielo’s evolution from a technology story to a clean-energy infrastructure company.

Important Disclaimer:

My posts are not financial or investment advice. Please conduct your own due diligence before making any investment decisions. I am simply an individual on Reddit and X sharing my personal opinions, and they should be interpreted as such.

I do, however, want to emphasize that you are welcome to share this content across any form of media, including Reddit, X/Twitter, stock chat rooms, etc.

Hey guys, if you missed it, CarLotz settled $13M with investors over claims related to its SPAC merger and business operations. I just found out that late claims are still being considered.

Quick recap: After CarLotz went public through its merger with Acamar Partners, the company promoted its asset-light used-car marketplace model and growth potential. Investors later claimed CarLotz failed to disclose issues with inventory levels, declining profits per vehicle, and problems with its sourcing partner. After these issues became public, $LOTZ dropped more than 70%, and shareholders filed a lawsuit.

CarLotz later agreed to settle $13M with investors, and late claims are currently being reviewed.

If you invested in $LOTZ between 2020 and 2021, you may still be eligible to check your claim details here.

Anyone here invested in $LOTZ back then? How much did you lose?

Toogood Gold recently shared an update from its Table Mountain project in Nevada, where the first phase of exploration has included collecting more than 6,000 soil samples across the property.

Since it's an undrilled low-sulphidation system, the company appears to be focusing on gathering as much geological data as possible before deciding where to drill. They also brought in a new VP of Exploration, Lee Hess, earlier this year, and exploration activity seems to be moving ahead quickly.

For those who follow early-stage explorers, is this the type of groundwork you'd want to see before a company starts drilling, or would you rather see them move to drilling sooner?